Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use

Details for Australian Patent Application No. 2005208911 (hide)

Owner Bayer Pharmaceuticals Corporation

Inventors Salhanick, Arthur I.; Buckholz, Thomas; Lumb, Kevin J.; Clairmont, Kevin

Agent Davies Collison Cave

Pub. Number AU-A-2005208911

PCT Pub. Number WO2005/072385

Priority 60/566,499 29.04.04 US; 60/539,550 27.01.04 US

Filing date 27 January 2005

Wipo publication date 11 August 2005

International Classifications

A61K 38/00 (2006.01) Medicinal preparations containing peptides

Event Publications

17 August 2006 PCT application entered the National Phase

  PCT publication WO2005/072385 Priority application(s): WO2005/072385

15 April 2010 Assignment before Grant

  Bayer Pharmaceuticals Corporation The application has been assigned to Bayer Healthcare LLC

19 August 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005208914-Osteoblast factor(s) that regulates human prostate cancer migration to and invasion of bone

2005208908-System and method for secure telephone and computer transactions